GO:0097332 response to antipsychotic drug: Pharmacogenomic Response, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0097332 response to antipsychotic drug describes any process by which a cell or organism changes state or activity following exposure to an antipsychotic drug stimulus.
• Antipsychotic drugs control agitated psychotic behaviour, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect.
• D2 receptor (DRD2) genetic variation is associated with clinical response to antipsychotic drug treatment in meta-analyses.
• Pharmacogenomic studies have identified multiple candidate genes, including DRD2, COMT, and other neurotransmitter-related loci, that influence antipsychotic drug response.
• Placebo-controlled trials and dose-response meta-analyses provide the evidence base for antipsychotic efficacy and discontinuation behaviour.
• CRISPR knockout, point mutation, knock-in, and overexpression models enable causal testing of candidate genes in response to antipsychotic drug exposure.
Description
GO:0097332 response to antipsychotic drug is a biological process ontology term that captures any process resulting in a change in state or activity of a cell or an organism as a result of an antipsychotic drug stimulus. Antipsychotic drugs are agents that control agitated psychotic behaviour, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. This term is therefore central to understanding how cells and organisms respond to a major class of psychotropic medication used in schizophrenia and related psychotic disorders. Researchers studying antipsychotic drug response need to connect clinical pharmacodynamics with molecular and cellular mechanisms, and GO:0097332 provides a formal framework for annotating those responses. The term is broad enough to encompass gene expression changes, enzyme production, secretion, movement, and other cellular activities triggered by antipsychotic exposure. Because antipsychotic drugs act primarily through dopamine D2 receptor blockade and related neurotransmitter systems, the response process intersects with pharmacogenomic variation in DRD2 and other genes. Meta-analyses of placebo-controlled trials have established that antipsychotic drugs are efficacious in acute schizophrenia, with response varying by dose, drug, and patient factors. Systematic reviews of dosing and discontinuation further show that the magnitude and persistence of response depend on how the drug is administered. Pharmacogenomic progress has highlighted that genetic variation in D2 receptor and COMT can modulate clinical response, making GO:0097332 a useful organizing principle for mechanistic and translational research. Understanding this process at the cellular level is essential for developing biomarkers, optimizing dosing, and designing new therapeutic strategies.
response to antipsychotic drug At A Glance
| GO ID | GO:0097332 |
|---|---|
| GO term | response to antipsychotic drug |
| Ontology | biological_process |
| Synonym | none |
| Definition | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an antipsychotic drug stimulus. Antipsychotic drugs are agents that control agitated psychotic behaviour, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. |
| Major function | Mediates cellular and organismal responses to antipsychotic drug exposure, including gene expression, enzyme production, secretion, and behavioural quieting. |
| Clinical context | Antipsychotic drugs are used to treat schizophrenia and acute psychotic states, with efficacy demonstrated in placebo-controlled trials. |
| Pharmacogenomic relevance | Genetic variation in DRD2 and COMT has been associated with clinical response to antipsychotic drug treatment. |
| Dosing relevance | Antipsychotic drug dosing influences study discontinuation and response magnitude in schizophrenia. |
What Is GO:0097332?
In our own words, GO:0097332 response to antipsychotic drug refers to any process that changes the state or activity of a cell or organism in terms of movement, secretion, enzyme production, gene expression, or similar outputs, following exposure to an antipsychotic drug stimulus. Antipsychotic drugs are defined as agents that control agitated psychotic behaviour, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. The term is a biological process and does not specify a single molecular pathway; instead, it encompasses the diverse cellular and organismal responses elicited by this drug class.
Why Is response to antipsychotic drug Important in Cell Biology?
GO:0097332 response to antipsychotic drug is important because antipsychotic drugs are a cornerstone of treatment for schizophrenia and other psychotic disorders, and understanding the biological response to these agents is essential for predicting efficacy, tolerability, and individualized dosing. Placebo-controlled trials have shown that antipsychotic drugs produce clinically meaningful symptom reduction in acute schizophrenia, but response varies substantially across patients. Pharmacogenomic studies indicate that genetic variation in DRD2 and COMT contributes to this variability, making the response process a target for biomarker development. Systematic reviews of dosing and discontinuation further highlight that how the drug is given affects whether patients stay on treatment and how well they respond. Thus, GO:0097332 provides a conceptual bridge between molecular pharmacology, clinical outcome, and experimental model systems.
• Antipsychotic drugs are first-line treatments for schizophrenia and acute psychotic states, and GO:0097332 captures the biological response to these agents.
• D2 receptor (DRD2) genetic variation is associated with clinical response to antipsychotic drug treatment in meta-analyses.
• COMT genetic variation has also been linked to clinical response to antipsychotic drug treatment in meta-analysis.
• Pharmacogenomic progress continues to identify candidate genes that modulate antipsychotic drug response.
• Dose-response meta-analyses show that antipsychotic dosing affects discontinuation and response in schizophrenia.
• Placebo response has increased in antipsychotic drug trials, complicating the interpretation of response signals.
• Single-arm meta-analyses of drug response help compare placebo-controlled and active-controlled trial designs.
• Understanding GO:0097332 supports development of personalized dosing and treatment strategies.
• Cellular models of antipsychotic drug response enable mechanistic dissection of gene expression and enzyme production changes.
• The term provides a standardized annotation target for functional genomics and CRISPR screening studies of antipsychotic response.
What Happens During response to antipsychotic drug?
Drug exposure and receptor engagement
In simple terms: The drug reaches the cell and binds to its targets, starting the response.
The response to antipsychotic drug begins when the drug interacts with cellular targets, most notably dopamine D2 receptors, which are central to antipsychotic efficacy. Antipsychotic drugs are defined by their ability to control agitated psychotic behaviour, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. Genetic variation in DRD2 modulates clinical response, indicating that receptor-level events are a key initial step in the response process. Pharmacogenomic studies have identified DRD2 as a major candidate gene influencing antipsychotic drug response.
Intracellular signaling and gene expression changes
In simple terms: Once the drug binds, the cell changes which genes it turns on or off.
Following receptor engagement, antipsychotic drug exposure leads to changes in gene expression and enzyme production, which are explicitly included in the GO:0097332 definition. These changes can involve neurotransmitter-related pathways and downstream signaling cascades that alter cellular state or activity. Pharmacogenomic research has highlighted that multiple genes, including COMT, contribute to the variability in antipsychotic drug response, suggesting that gene expression and enzyme activity are important response components.
Neurotransmitter metabolism and secretion
In simple terms: The cell adjusts how it makes, releases, and breaks down chemical messengers.
The GO:0097332 definition includes secretion and enzyme production as possible outputs of the response to antipsychotic drug stimulus. COMT is an enzyme involved in catecholamine metabolism, and its genetic variation has been associated with clinical response to antipsychotic drug treatment in meta-analysis. This suggests that antipsychotic drug response can involve changes in neurotransmitter metabolism and secretion, which are measurable cellular activities.
Clinical and behavioural response
In simple terms: At the whole-organism level, the drug reduces psychotic symptoms and quiets agitation.
At the organismal level, the response to antipsychotic drug includes reduction of psychotic symptoms and quieting of agitated behaviour, as reflected in the definition. Placebo-controlled trials have demonstrated that antipsychotic drugs are efficacious in acute schizophrenia, with response rates that vary by drug, dose, and patient characteristics. Dose-response meta-analyses show that antipsychotic dosing influences study discontinuation, which is a clinically relevant aspect of the response process. Single-arm meta-analyses further characterize drug response in placebo-controlled versus active-controlled trials.
Pharmacogenomic modulation of response
In simple terms: A person's genes can make them respond better or worse to the drug.
Genetic variation in DRD2 and COMT has been associated with clinical response to antipsychotic drug treatment, indicating that the response process is modulated by pharmacogenomic factors. Recent progress in pharmacogenomics of antipsychotic drug response has identified additional candidate genes and pathways that may influence efficacy and tolerability. These findings support the view that GO:0097332 encompasses a genetically variable biological process that can be studied with functional genomics approaches.
Key Genes Involved in GO:0097332 response to antipsychotic drug
The following genes and proteins have been implicated in the response to antipsychotic drugs through pharmacogenomic and clinical studies.
| Gene | Major Role | Research Relevance |
|---|---|---|
| DRD2 | Dopamine D2 receptor; primary target of antipsychotic drugs | Genetic variation associated with clinical response to antipsychotic drug treatment in meta-analysis |
| COMT | Catechol-O-methyltransferase; enzyme involved in catecholamine metabolism | Genetic variation associated with clinical response to antipsychotic drug treatment in meta-analysis |
| DRD3 | Dopamine D3 receptor | Candidate gene in pharmacogenomics of antipsychotic drug response |
| DRD4 | Dopamine D4 receptor | Candidate gene in pharmacogenomics of antipsychotic drug response |
| HTR2A | Serotonin 2A receptor | Candidate gene in pharmacogenomics of antipsychotic drug response |
| HTR2C | Serotonin 2C receptor | Candidate gene in pharmacogenomics of antipsychotic drug response |
| CYP2D6 | Cytochrome P450 enzyme involved in drug metabolism | Pharmacogenomic candidate influencing antipsychotic drug exposure and response |
| CYP1A2 | Cytochrome P450 enzyme involved in drug metabolism | Pharmacogenomic candidate influencing antipsychotic drug exposure and response |
| CYP3A4 | Cytochrome P450 enzyme involved in drug metabolism | Pharmacogenomic candidate influencing antipsychotic drug exposure and response |
| AKT1 | Serine/threonine kinase in dopamine signaling | Candidate gene in pharmacogenomics of antipsychotic drug response |
| BDNF | Brain-derived neurotrophic factor | Candidate gene in pharmacogenomics of antipsychotic drug response |
| DTNBP1 | Dysbindin; involved in synaptic function | Candidate gene in pharmacogenomics of antipsychotic drug response |
| NRG1 | Neuregulin 1; involved in neuronal signaling | Candidate gene in pharmacogenomics of antipsychotic drug response |
| RGS4 | Regulator of G-protein signaling 4 | Candidate gene in pharmacogenomics of antipsychotic drug response |
| GAD1 | Glutamate decarboxylase 1; GABA synthesis | Candidate gene in pharmacogenomics of antipsychotic drug response |
| GRM3 | Metabotropic glutamate receptor 3 | Candidate gene in pharmacogenomics of antipsychotic drug response |
| SLC6A3 | Dopamine transporter | Candidate gene in pharmacogenomics of antipsychotic drug response |
How Is response to antipsychotic drug Regulated?
The response to antipsychotic drug is regulated at multiple levels, including genetic variation in drug targets and metabolizing enzymes. DRD2 genetic variation modulates clinical response, indicating that receptor-level regulation is important. COMT genetic variation also influences response, suggesting that catecholamine metabolism regulates the process. Pharmacogenomic studies have identified additional candidate genes in neurotransmitter and metabolic pathways that may regulate antipsychotic drug response. Dosing regimens further regulate the magnitude and persistence of response, as shown by dose-response meta-analyses of discontinuation.
response to antipsychotic drug and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| DRD2 | Schizophrenia; antipsychotic drug response | Knockout or point-mutation cell lines to test receptor-mediated signaling |
| COMT | Schizophrenia; catecholamine metabolism and drug response | Knockout or overexpression models to measure enzyme activity and response |
| CYP2D6 | Drug metabolism; antipsychotic exposure | Knock-in or knockout models to study metabolic capacity |
| AKT1 | Dopamine signaling; antipsychotic response | Knockout or point-mutation models to dissect signaling |
| BDNF | Neuroplasticity; antipsychotic response | Overexpression or knockout models to assess neurotrophic effects |
Schizophrenia and psychotic disorders
GO:0097332 response to antipsychotic drug is most directly relevant to schizophrenia and other psychotic disorders, where antipsychotic drugs are used to control agitated psychotic behaviour, alleviate acute psychotic states, and reduce psychotic symptoms. Placebo-controlled trials have established the efficacy of antipsychotic drugs in acute schizophrenia, and meta-analyses have identified predictors of response. Dose-response meta-analyses show that antipsychotic dosing affects study discontinuation, which is a key clinical outcome in schizophrenia. Pharmacogenomic variation in DRD2 and COMT contributes to interindividual differences in response, linking the biological process to disease management.
Pharmacogenomic variability in treatment response
Genetic variation in DRD2 and COMT has been associated with clinical response to antipsychotic drug treatment, making pharmacogenomics a key lens for understanding GO:0097332. Recent progress in pharmacogenomics of antipsychotic drug response has expanded the list of candidate genes and pathways that may explain why some patients respond better than others. These findings have implications for personalized dosing and for predicting adverse effects, although further validation is needed.
Trial design and placebo response
The response to antipsychotic drug in clinical trials is influenced by placebo response, which has increased over time and complicates the interpretation of efficacy signals. Single-arm meta-analyses of drug response in placebo-controlled versus active-controlled trials provide additional context for how response is measured and compared. These methodological issues are relevant to how GO:0097332 is studied in human populations.
From response to antipsychotic drug-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does DRD2 mediate cellular response to antipsychotic drugs? | DRD2 knockout cell line |
| Does a specific DRD2 variant alter response? | DRD2 point-mutation knock-in cell line |
| Does COMT activity modulate response? | COMT knockout or overexpression cell line |
| Does CYP2D6 metabolism affect drug exposure? | CYP2D6 knock-in or knockout hepatocyte model |
| Does AKT1 signaling contribute to response? | AKT1 knockout or point-mutation cell line |
| Does BDNF overexpression enhance response? | BDNF overexpression cell line |
How to Study the response to antipsychotic drug Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Pharmacogenomic association | Genetic variant association with drug response | Identifying DRD2 and COMT variants linked to response |
| Placebo-controlled trial | Efficacy of antipsychotic drug versus placebo | Establishing clinical response in schizophrenia |
| Dose-response meta-analysis | Relationship between dose and discontinuation | Optimizing dosing strategies |
| Single-arm meta-analysis | Drug response in different trial designs | Comparing placebo-controlled and active-controlled trials |
| Gene expression assay | Changes in mRNA levels after drug exposure | Measuring cellular response to antipsychotic drugs |
| Enzyme activity assay | Production or activity of enzymes such as COMT | Assessing metabolic response |
| CRISPR knockout | Loss-of-function effects on drug response | Testing causal role of candidate genes |
| CRISPR knock-in | Effect of specific variants on drug response | Modeling pharmacogenomic variants |
Pharmacogenomic association studies
Pharmacogenomic studies use candidate-gene and genome-wide approaches to identify genetic variants associated with antipsychotic drug response. Meta-analyses of DRD2 and COMT have provided evidence for association with clinical response, while broader pharmacogenomic reviews summarize additional candidate genes. These methods link GO:0097332 to human genetic variation and clinical outcomes.
Clinical trial and meta-analytic methods
Placebo-controlled trials, dose-response meta-analyses, and single-arm meta-analyses are used to quantify antipsychotic drug efficacy and discontinuation. These methods provide the clinical evidence base for the response process and help identify predictors of outcome.
Cellular and molecular assays
Cellular models can measure changes in gene expression, enzyme production, and secretion following antipsychotic drug exposure, which are core outputs of GO:0097332. Such assays can be combined with CRISPR editing to test causal roles of candidate genes.
Functional genomics and CRISPR screening
CRISPR knockout, point mutation, knock-in, and overexpression models allow systematic testing of candidate genes in antipsychotic drug response. These approaches can be scaled to library screening to identify novel modulators of GO:0097332.
How CRISPR Can Be Used to Study GO:0097332 response to antipsychotic drug
Knockout
CRISPR knockout of candidate genes such as DRD2 or COMT can test whether loss of function alters cellular or organismal response to antipsychotic drugs. Such models help determine causality in the pharmacogenomic associations observed in human studies.
Point Mutation
CRISPR point mutation can introduce specific variants identified in pharmacogenomic studies, such as DRD2 or COMT polymorphisms, to test their functional impact on antipsychotic drug response. This approach bridges genetic association and mechanism.
Knock-in
CRISPR knock-in can insert human variant alleles or reporter tags into endogenous loci to study drug response in a physiologically relevant context. Knock-in models are particularly useful for modeling pharmacogenomic variants in drug metabolism genes such as CYP2D6.
Overexpression
CRISPR overexpression or cDNA overexpression can elevate levels of candidate genes such as BDNF or COMT to test whether increased activity enhances or dampens antipsychotic drug response. Overexpression models complement knockout studies by probing gain-of-function effects.
How EDITGENE Supports response to antipsychotic drug Research
Researchers studying response to antipsychotic drug-related genes often need to determine whether a candidate gene is causally involved in the cellular or organismal response to drug exposure. EDITGENE provides CRISPR-based cell model services that enable knockout, point mutation, knock-in, and overexpression studies of genes such as DRD2, COMT, and CYP2D6, as well as library screening and bioinformatics support.
Contact EDITGENE today to design your custom CRISPR model for response to antipsychotic drug research.
Frequently Asked Questions About response to antipsychotic drug
What is GO:0097332 response to antipsychotic drug?
GO:0097332 is a biological process ontology term describing any process that changes the state or activity of a cell or organism as a result of an antipsychotic drug stimulus, including changes in movement, secretion, enzyme production, and gene expression.
What are antipsychotic drugs?
Antipsychotic drugs are agents that control agitated psychotic behaviour, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect.
What genes are involved in response to antipsychotic drug?
Genes implicated in antipsychotic drug response include DRD2, COMT, CYP2D6, AKT1, BDNF, and others identified in pharmacogenomic studies.
How does DRD2 affect antipsychotic drug response?
DRD2 genetic variation has been associated with clinical response to antipsychotic drug treatment in meta-analysis, indicating that the dopamine D2 receptor modulates response.
How does COMT affect antipsychotic drug response?
COMT genetic variation has been associated with clinical response to antipsychotic drug treatment in meta-analysis, suggesting a role for catecholamine metabolism.
What is the role of pharmacogenomics in antipsychotic drug response?
Pharmacogenomics studies how genetic variation influences antipsychotic drug response, with recent progress identifying multiple candidate genes and pathways.
How is antipsychotic drug response measured in clinical trials?
Response is measured in placebo-controlled trials, dose-response meta-analyses, and single-arm meta-analyses that assess symptom reduction and discontinuation.
Why does antipsychotic drug dosing matter?
Dose-response meta-analyses show that antipsychotic dosing affects study discontinuation and response magnitude in schizophrenia.
What is the placebo response in antipsychotic drug trials?
Placebo response has increased over time in antipsychotic drug trials, complicating the interpretation of efficacy signals.
How can CRISPR help study response to antipsychotic drug?
CRISPR knockout, point mutation, knock-in, and overexpression models can test causal roles of candidate genes such as DRD2 and COMT in antipsychotic drug response.
Conclusion
GO:0097332 response to antipsychotic drug provides a formal biological process framework for studying how cells and organisms react to antipsychotic medication, encompassing gene expression, enzyme production, secretion, and behavioural quieting. Clinical and pharmacogenomic evidence links this process to schizophrenia treatment outcomes and to genetic variation in DRD2, COMT, and other candidate genes. Dose-response and trial-design meta-analyses further inform how response is measured and optimized. CRISPR-based cell models offer a powerful way to test causality and discover new modulators of this response process.
References
- 1. Leucht S et al.. 2024. Antipsychotic Drugs: A Concise Review of History, Classification, Indications, Mechanism, Efficacy, Side Effects, Dosing, and Clinical Application.. Am J Psychiatry 181(10):865-878 PMID: 39350614
- 2. Tian J et al.. 2025. Antipsychotic drug dosing and study discontinuation in schizophrenia: A systematic review and dose-response meta-analysis.. Eur Neuropsychopharmacol 94:51-58 PMID: 40056667
- 3. Leucht S et al.. 2017. Sixty Years of Placebo-Controlled Antipsychotic Drug Trials in Acute Schizophrenia: Systematic Review, Bayesian Meta-Analysis, and Meta-Regression of Efficacy Predictors.. Am J Psychiatry 174(10):927-942 PMID: 28541090
- 4. Zhang JP et al.. 2010. D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis.. Am J Psychiatry 167(7):763-72 PMID: 20194480
- 5. Zhang JP et al.. 2018. Recent Progress in Pharmacogenomics of Antipsychotic Drug Response.. Curr Psychiatry Rep 20(4):24 PMID: 29589131
- 6. Chen H et al.. 2015. [COMT genetic variation and clinical response to antipsychotic drug treatment: A Meta-analysis].. Zhong Nan Da Xue Xue Bao Yi Xue Ban 40(6):623-31 PMID: 26164511
- 7. Leucht S et al.. 2013. Increasing placebo response in antipsychotic drug trials: let's stop the vicious circle.. Am J Psychiatry 170(11):1232-4 PMID: 24185236
- 8. Dong S et al.. 2024. Single-arm meta-analysis of drug response in placebo-controlled versus active-controlled antipsychotic drug trials in schizophrenia.. Eur Neuropsychopharmacol 84:21-26 PMID: 38643697
